Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs
2025 ASCO Annual Meeting
Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508).
The ASCO Post Staff
Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting.
The ASCO Post Staff
Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract 5014).
The ASCO Post Staff
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011).
The ASCO Post Staff
Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or gastroesophageal junction (GEJ) cancer (LBA5).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
